Safety Study of AMI MultiStem® to Treat Heart Attacks

Phase 1 Completed 25 enrolled Healios K.K. Angiotech Pharmaceuticals · collab PPD Development, LP · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if escalating doses of AMI MultiStem® delivered by catheter can safely be given to patients that have had a recent heart attack treated with stent implantation.

Timeline

Start: 2008-05
Primary completion: 2010-03
Completion: 2012-02

Publications

Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn FO, Strasser D, Ting AE, Sherman W. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res. 2012 Jan 20;110(2):304-11. doi: 10.1161/CIRCRESAHA.111.253427. Epub 2011 Nov 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMI MultiStem®	Unknown	20 cells	Other
Subject	AMI MultiStem®	Unknown	50 cells	Other
Subject	AMI MultiStem®	Unknown	100 cells	Other

Safety Study of AMI MultiStem® to Treat Heart Attacks

Summary

Timeline

Publications

Drugs

Indications